Daratumumab-based treatment of monoclonal gammopathy–associated angioedema due to acquired C1-inhibitor deficiency
-
Published:2024-11
Issue:4
Volume:3
Page:100322
-
ISSN:2772-8293
-
Container-title:Journal of Allergy and Clinical Immunology: Global
-
language:en
-
Short-container-title:Journal of Allergy and Clinical Immunology: Global
Author:
Petersen Remy S.ORCID,
Fijen Lauré M.,
Franssen Laurens E.,
Vos Josephine M.I.,
Cohn Danny M.
Reference9 articles.
1. Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group;Cicardi;Allergy,2014
2. Angioedema due to acquired deficiency of C1-inhibitor: a cohort study in Spain and a comparison with other series;Baeza;J Allergy Clin Immunol Pract,2022
3. Long-term effects upon rituximab treatment of acquired angioedema due to C1-inhibitor deficiency;Levi;Allergy,2019
4. Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications;Fermand;Blood,2018
5. Overall survival with daratumumab, lenalidomide, and dexamethasone in previously treated multiple myeloma (POLLUX): a randomized, open-label, phase III trial;Dimopoulos;J Clin Oncol,2023